(Q43263183)

17 November 2017

title

Beneficial effects of telmisartan in an HIV+ diabetic insulin-dependent patient (English)

1 reference

17 November 2017

C Ucciferri

1

1 reference

17 November 2017

P Mancino

series ordinal

2

1 reference

17 November 2017

J Vecchiet

series ordinal

3

1 reference

17 November 2017

K Falasca

series ordinal

4

1 reference

17 November 2017

publication date

1 July 2009

1 reference

International Journal of Immunopathology and Pharmacology

17 November 2017

published in

1 reference

17 November 2017

volume

22

1 reference

17 November 2017

issue

3

1 reference

17 November 2017

page(s)

853-857

1 reference

17 November 2017

cites work

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200334

Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200334

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200334

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200334

Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200334

Possible beneficial effect of telmisartan on glycemic control in diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200334

Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200334

Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200334

Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200334

Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200334

Effects of telmisartan therapy on metabolic profiles and serum high molecular weight (HMW)-adiponectin level in Japanese male hypertensive subjects with abdominal obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200334

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200334

Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200334

10.1177/039463200902200334

21 January 2018

Identifiers

DOI

1 reference

17 November 2017

1 reference